4D Molecular Therapeutics Inc (FDMT) - Total Assets
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) holds total assets worth $566.71 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore FDMT debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
4D Molecular Therapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See net assets of 4D Molecular Therapeutics Inc for net asset value and shareholders' equity analysis.
4D Molecular Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
4D Molecular Therapeutics Inc's total assets of $566.71 Million consist of 72.9% current assets and 27.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4D Molecular Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 4D Molecular Therapeutics Inc's current assets represent 72.9% of total assets in 2025, a decrease from 89.7% in 2017.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2025, down from 87.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
4D Molecular Therapeutics Inc Competitors by Total Assets
Key competitors of 4D Molecular Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
4D Molecular Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.39 | 14.92 | 19.01 |
| Quick Ratio | 9.39 | 14.92 | 19.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $369.15 Million | $405.78 Million | $250.59 Million |
4D Molecular Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between 4D Molecular Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | $566.71 Million |
| Market Capitalization | $515.62 Million USD |
Valuation Analysis
Near Book Valuation: The market values 4D Molecular Therapeutics Inc's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: 4D Molecular Therapeutics Inc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual total assets of 4D Molecular Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $566.71 Million | +1.13% |
| 2024-12-31 | $560.38 Million | +64.87% |
| 2023-12-31 | $339.89 Million | +29.81% |
| 2022-12-31 | $261.85 Million | -25.92% |
| 2021-12-31 | $353.49 Million | +22.60% |
| 2020-12-31 | $288.33 Million | +395.12% |
| 2019-12-31 | $58.23 Million | -39.95% |
| 2018-12-31 | $96.97 Million | +254.94% |
| 2017-12-31 | $27.32 Million | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more